(Q43971241)

28 November 2017

title

Melanoma prognostics and personalized therapeutics at a crossroad (English)

1 reference

28 November 2017

Roger S Lo

1

1 reference

28 November 2017

language of work or name

English

0 references

publication date

1 February 2013

1 reference

Journal of Investigative Dermatology

28 November 2017

published in

1 reference

28 November 2017

volume

133

1 reference

28 November 2017

issue

2

1 reference

28 November 2017

page(s)

292-295

1 reference

https://scigraph.springernature.com/pub.10.1038/jid.2012.386

28 November 2017

exact match

0 references

cites work

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.386

7 January 2021

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.386

7 January 2021

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.386

7 January 2021

BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.386

7 January 2021

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.386

7 January 2021

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.386

7 January 2021

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.386

7 January 2021

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.386

7 January 2021

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.386

7 January 2021

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.386

7 January 2021

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.386

7 January 2021

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

1 reference

https://api.crossref.org/works/10.1038%2FJID.2012.386

7 January 2021

Identifiers

DOI

10.1038/JID.2012.386

1 reference

Dimensions Publication ID

28 November 2017

1049622918

0 references

1 reference